179 related articles for article (PubMed ID: 38321229)
21. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
22. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
24. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
27. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Togitani K; Asagiri T; Kamioka M; Kojima K
Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
[TBL] [Abstract][Full Text] [Related]
28. Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Lu X; Song X; Ye Y; Liu X; Zhou Y; Zhang L; Wang J; Ying B; Wang L
Mol Biol Rep; 2011 Jun; 38(5):3101-5. PubMed ID: 20127176
[TBL] [Abstract][Full Text] [Related]
29. Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
Chen H; Liu KY; Xu LP; Chen YH; Zhang XH; Wang Y; Qin YZ; Liu YR; Lai YY; Huang XJ
Leuk Res; 2017 Aug; 59():136-141. PubMed ID: 28654842
[TBL] [Abstract][Full Text] [Related]
30. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
31. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
32. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
[TBL] [Abstract][Full Text] [Related]
33. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
34. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
Shimoda K; Takahashi N; Kirito K; Iriyama N; Kawaguchi T; Kizaki M
Int J Hematol; 2020 Sep; 112(3):268-291. PubMed ID: 32783166
[No Abstract] [Full Text] [Related]
35. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
36. The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Kayastha GK; Ranjitkar N; Gurung R; Kc RK; Karki S; Shrestha R; Rajbhandari P; Thapa RK; Poudyal B; Acharya P; Roberts DJ; Hayes B; Zimmerman M; Basnyat B
Br J Haematol; 2017 Jun; 177(6):1000-1007. PubMed ID: 28467002
[TBL] [Abstract][Full Text] [Related]
37. [Chronic myeloid leukemia: update on treatment and survival prediction].
Sasaki K
Rinsho Ketsueki; 2020; 61(9):1179-1186. PubMed ID: 33162514
[TBL] [Abstract][Full Text] [Related]
38. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
[TBL] [Abstract][Full Text] [Related]
40. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]